
    
      A randomized, double-blind, placebo-controlled study to evaluate the effects of GW679769 on
      Current Perception Threshold (CPT) following a single 150 mg dose (Part A) and to evaluate
      the effect of CPT and symptoms of overactive bladder following 28 days of repeat dosing with
      120 mg GW679769 administered once daily (Part B) in patients with neurogenic bladder due to
      incomplete spinal cord injury
    
  